Recce Pharmaceuticals (RCE) Q1 2027 TU earnings summary

Executive summary

• HREC approved an amendment adding a 208-participant, randomised active-comparator non-inferiority component to the pivotal Australian Phase 3 trial of RECCE® 327 Topical Gel (R327G) for diabetic foot infections.

• A Vietnamese Family 4 patent was granted for RECCE® anti-infectives, extending protection to 2041; this is the eighth grant in the family.

• The quarter included A$3.6 million in R&D tax rebate receipts and completion of the Share Purchase Plan, bringing Placement and SPP proceeds to A$6.4 million before costs.

Financial highlights

• Q1 FY2027 net cash used in operating activities was A$3.833 million; quarter-end cash was A$1.044 million before the expected overseas R&D rebate.

• R&D outlays were A$5.783 million; interest received was A$123,911, and related-party payments were A$670,252.

• A$3.6 million was received under the R&D Tax Incentive in July; total FY2025 rebates reached ~A$8.9 million.

• A further ~A$7.5 million FY2026 R&D Tax Incentive rebate was expected in the near term, supporting Phase 3 programs and strategic objectives.

Outlook and guidance

• A 75-patient Indonesian Phase 3 dataset was submitted for unblinded DMC evaluation post-quarter; a DMC meeting could occur as soon as mid-November 2026, while recruitment and dosing continue.

• Australian Phase 3 recruitment continues under the existing protocol ahead of the amendment; interim analysis is planned after 104 participants complete treatment or withdraw prematurely.

• Near-term priorities include Phase 3 data-review milestones and regulatory and commercial preparations across key markets.